ArticleJournal of geriatric cardiology : JGC2026
Ketogenic diet, cardiometabolic diseases and aging.
Article in Journal of geriatric cardiology : JGC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ketogenic diet (KD), characterized by a high-fat, moderate-protein, and low-carbohydrate macronutrient composition, has gained growing interest as a potential nutritional approach to cardiometabolic diseases and aging. Emerging evidence suggests that ketone bodies, particularly β-hydroxybutyrate, act not only as alternative energy substrates but also as signaling molecules that influence vascular, metabolic, and epigenetic pathways. This review summarizes current knowledge on the cardiovascular and metabolic implications of KD, emphasizing endothelial function, cardiac energy metabolism, lipid profile, and blood pressure regulation. Experimental and clinical data indicate that KD enhances endothelial antioxidant capacity via Nrf2 activation and eNOS upregulation, reduces cellular senescence, and modulates epigenetic regulators such as histone β-hydroxybutyrylation and SIRT1. In heart failure, acute ketone supplementation improves cardiac output and energetics, while chronic adherence to KD may impair hepatic ketogenesis and lipid homeostasis, potentially offsetting its benefits. Evidence in hypertension and dyslipidemia remains controversial, with short-term improvements often contrasted by long-term elevations in LDL cholesterol and arterial stiffness. In patients with type 2 diabetes, KD promotes glycemic control and insulin sensitivity, yet the sustainability and cardiovascular safety of prolonged use are uncertain. Overall, KD represents a promising but complex therapeutic tool whose efficacy depends on individual metabolic context, diet composition, and duration. A balanced, intermittent, or cyclic ketogenic approach may offer a safer strategy to harness its cardiometabolic and anti-aging benefits.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.